<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122979</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_L_04737</org_study_id>
    <nct_id>NCT01122979</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.</brief_title>
  <acronym>DINAMO</acronym>
  <official_title>National (Brazil), Phase IV, Multicentric, Open Label, Parallel, Comparative Study of the Use of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      &gt;To obtain an estimation for both treatment groups of the proportion of patients that reach
      the target of HbA1c &lt;= 7% without confirmed nocturnal hypoglycaemia in each treatment group.

      Secondary Objectives:

        -  Glycemic control, measured by HbA1c and FPG (fasting plasma glucose) at baseline and
           after each period of treatment.

        -  Incidence of confirmed symptomatic and nocturnal hypoglycemia.

        -  Incidence of confirmed severe hypoglycemia (&lt; 36mg/dL or need of help to recover).
           &gt;Weight variation for each period of treatment.

        -  Creatinine clearance at baseline and after each period of treatment.

        -  Overall safety: Incidence of adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients that reach the target of HbA1c ≤7% without confirmed nocturnal hypoglycaemia in each treatment group and the respective CI 90%.</measure>
    <time_frame>From visit 1 (Day 1) to visit 13 (Day 169)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that reach the target of HbA1c ≤7% and proportion of patients reaching the target of Fasting Plasma Glucose (FPG ≤100mg/dL).</measure>
    <time_frame>From baseline and Visit 13 (Day 169)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of confirmed symptomatic and nocturnal hypoglycemias: plasma glucose measurement &lt;= 70mg/dL.</measure>
    <time_frame>From baseline and Visit 13 (Day 169)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of confirmed severe hypoglycemia: plasma glucose level &lt; 36 mg/dL (2 mmol/L) or with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration</measure>
    <time_frame>From baseline and Visit 13 (Day 169)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight variation</measure>
    <time_frame>From baseline to the end of treatment at visit 13 (day 169)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance variation</measure>
    <time_frame>From baseline to the end of treatment at visit 13 (day 169)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>group 1: insulin glargine + insulin glulisine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>insulin glargine once daily + glulisine at meal times</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 NPH insulin + regular insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPH insulin (isophane insulin) (2 or more divided doses) + regular insulin at meal times</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE</intervention_name>
    <description>Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia</description>
    <arm_group_label>group 1: insulin glargine + insulin glulisine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH insulin (insulin isophane)</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia</description>
    <arm_group_label>group 2 NPH insulin + regular insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLULISINE</intervention_name>
    <description>Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia</description>
    <arm_group_label>group 1: insulin glargine + insulin glulisine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular insulin</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia</description>
    <arm_group_label>group 2 NPH insulin + regular insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Type 2 diabetes and renal failure in use of NPH regular insulin or fast-acting analog
             and HbA1c &gt;= 8%.

          -  Albuminuria or microalbuminuria diabetic retinopathy.

          -  Creatinine clearance &lt; 60 mL/min/1,73 m2 and &gt;30 mL/min/1,73 m2

        Exclusion criteria:

          -  Hypersensibility to insulin glargine or any other component of the insulin
             formulation.

          -  Use of investigational medications during the last 12 months or use of any
             investigational insulin preparation during the last 4 months.

          -  History of diabetic ketoacidosis or positive GAD antibodies.

          -  Advanced retinopathy needing laser therapy.

          -  Diagnosed advanced neuropathy

          -  Severe hepatic disease or active hepatitis.

          -  Cardiac failure class III or IV (NYHA).

          -  Patients on hemodialysis.

          -  Diagnosed cancer.

          -  Active infection.

          -  Current therapy with steroids.

          -  Patients with recognized or suspected endocrine disorders associated with increased
             insulin resistance, acromegaly, or hyperthyroidism.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 076-007</name>
      <address>
        <city>Curitiba</city>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-010</name>
      <address>
        <city>Fortaleza</city>
        <zip>60015-052</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-001</name>
      <address>
        <city>Fortaleza</city>
        <zip>60115-282</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-003</name>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-250</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-005</name>
      <address>
        <city>São Paulo</city>
        <zip>01244-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-013</name>
      <address>
        <city>São Paulo</city>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-004</name>
      <address>
        <city>São Paulo</city>
        <zip>01323-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-002</name>
      <address>
        <city>São Paulo</city>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-009</name>
      <address>
        <city>São Paulo</city>
        <zip>o4039-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076-006</name>
      <address>
        <city>Taguatinga</city>
        <zip>72155000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

